References
- right TL, Lau JY. Clinical aspects of hepatitis B virus infection. Lancet 1993; 342: 1340–4
- Tillmann HL, Hadem J, Leifeld L, Zachou K, Canbay A, Eisenbach C, et al. Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicentre experience. J Viral Hepat 2006; 13: 256–63
- Schiff E, Simsek H, Lee WM, Chao YC, Sette H, Jr, Janssen HL, et al. Efficacy and safety of entecavir in patients with chronic hepatitis B and advanced hepatic fibrosis or cirrhosis. Am J Gastroenterology 2008; 103: 2776–83
- Lisotti A, Azzaroli F, Buonfiglioli F, Montagnani M, Alessandrelli F, Mazzella G. Lamivudine: treatment for severe acute HBV hepatitis. Int J Med Sci 2008; 5: 309–12
- Girke J, Wedemeyer H, Wiegand J, Manns MP, Tillmann HL. Acute hepatitis B: is antiviral therapy indicated? Two case reports. Dtsch Med Wochenschr 2008; 133: 1178–82
- Kumar M, Satapathy S, Monga R, Das K, Hissar S, Pande C, et al. A randomized controlled trial of lamivudine to treat acute hepatitis B. Hepatology 2007; 45: 97–101
- Hoofnagle JH, Doo E, Liang TJ, Fleischer R, Lok AS. Management of hepatitis B: summary of a clinical research workshop. Hepatology 2007; 45: 1056–75